The Role of N⁶-Methyladenosine RNA Modification in Platinum Resistance

References

• Soerjomataram I , BrayF. Planning for tomorrow: global cancer incidence and the role of prevention 2020–2070. Nat. Rev. Clin. Oncol.18, 663–672 (2021).
   PubMed Web of Science ®Google Scholar
• Hulvat MC . Cancer incidence and trends. Surg. Clin. North Am.100, 469–481 (2020).
   PubMed Web of Science ®Google Scholar
• Ogrinc N , SaudemontP , TakatsZ , SalzetM , FournierI. Cancer surgery 2.0: guidance by real-time molecular technologies. Trends Mol. Med.27, 602–615 (2021).
   PubMed Web of Science ®Google Scholar
• Huang RX , ZhouPK. DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer. Signal Transduct. Target Ther.5, 60 (2020).
   PubMed Web of Science ®Google Scholar
• Sadeghian M , RahmaniS , KhalesiS , HejaziE. A review of fasting effects on the response of cancer to chemotherapy. Clin. Nutr.40, 1669–1681 (2021).
   PubMed Web of Science ®Google Scholar
• Tan S , LiD , ZhuX. Cancer immunotherapy: pros, cons and beyond. Biomed. Pharmacother.124, 109821 (2020).
   PubMed Web of Science ®Google Scholar
• Santucci C , CarioliG , BertuccioPet al. Progress in cancer mortality, incidence, and survival: a global overview. Eur. J. Cancer Prev.29, 367–381 (2020).
   PubMed Web of Science ®Google Scholar
• Ward RA , FawellS , Floc’hNet al. Challenges and opportunities in cancer drug resistance. Chem. Rev.121, 3297–3351 (2021).
   PubMed Web of Science ®Google Scholar
• Marine JC , DawsonSJ , DawsonMA. Non-genetic mechanisms of therapeutic resistance in cancer. Nat. Rev. Cancer20, 743–756 (2020).
   PubMed Web of Science ®Google Scholar
• Rottenberg S , DislerC , PeregoP. The rediscovery of platinum-based cancer therapy. Nat. Rev. Cancer21, 37–50 (2021).
   PubMed Web of Science ®Google Scholar
• Makovec T . Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy. Radiol. Oncol.53, 148–158 (2019).
   PubMed Web of Science ®Google Scholar
• Zhou J , KangY , ChenLet al. The drug-resistance mechanisms of five platinum-based antitumor agents. Front. Pharmacol.11, 343 (2020).
   PubMed Web of Science ®Google Scholar
• Mora Y , ReyesME , ZanellaLet al. Resistance to platinum-based cancer drugs: a special focus on epigenetic mechanisms. Pharmacogenomics22, 777–790 (2021).
   PubMed Web of Science ®Google Scholar
• Tang Y , ChenK , SongBet al. m6A-Atlas: a comprehensive knowledgebase for unraveling the N6-methyladenosine (m6A) epitranscriptome. Nucleic Acids Res.49, D134–D143 (2021).
   PubMed Web of Science ®Google Scholar
• Xu Z , PengB , CaiYet al. N6-methyladenosine RNA modification in cancer therapeutic resistance: current status and perspectives. Biochem. Pharmacol.182, 114258 (2020).
   PubMed Web of Science ®Google Scholar
• Lan Q , LiuPY , BellJLet al. The emerging roles of RNA m(6)A methylation and demethylation as critical regulators of tumorigenesis, drug sensitivity, and resistance. Cancer Res.81, 3431–3440 (2021).
   PubMed Web of Science ®Google Scholar
• Nie S , ZhangL , LiuJet al. ALKBH5-HOXA10 loop-mediated JAK2 m6A demethylation and cisplatin resistance in epithelial ovarian cancer. J. Exp. Clin. Cancer Res.40, 284 (2021).
   PubMed Web of Science ®Google Scholar
• Hao L , WangJM , LiuBQet al. m6A-YTHDF1-mediated TRIM29 upregulation facilitates the stem cell-like phenotype of cisplatin-resistant ovarian cancer cells. Biochim. Biophys. Acta Mol. Cell. Res.1868, 118878 (2021).
   PubMed Web of Science ®Google Scholar
• Zhou S , BaiZL , XiaDet al. FTO regulates the chemo-radiotherapy resistance of cervical squamous cell carcinoma (CSCC) by targeting β-catenin through mRNA demethylation. Mol. Carcinog.57, 590–597 (2018).
   PubMed Web of Science ®Google Scholar
• Wu M , ChenG , LiaoX , XiaoL , ZhengJ. YTHDF2 interference suppresses the EMT of cervical cancer cells and enhances cisplatin chemosensitivity by regulating AXIN1. Drug Dev. Res.83(5), 1190–1200 (2022).
   PubMed Web of Science ®Google Scholar
• Lin X , WangF , ChenJet al. N(6)-methyladenosine modification of CENPK mRNA by ZC3H13 promotes cervical cancer stemness and chemoresistance. Mil. Med. Res.9, 19 (2022).
   PubMed Web of Science ®Google Scholar
• Jin D , GuoJ , WuYet al. m(6)A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis. J. Hematol. Oncol.12, 135 (2019).
   PubMed Web of Science ®Google Scholar
• Shi L , GongY , ZhuoL , WangS , ChenS , KeB. Methyltransferase-like 3 upregulation is involved in the chemoresistance of non-small cell lung cancer. Ann. Transl. Med.10, 139 (2022).
   PubMed Web of Science ®Google Scholar
• Xie H , YaoJ , WangY , NiB. Exosome-transmitted circVMP1 facilitates the progression and cisplatin resistance of non-small cell lung cancer by targeting miR-524-5p-METTL3/SOX2 axis. Drug Deliv.29, 1257–1271 (2022).
   PubMed Web of Science ®Google Scholar
• Lan H , LiuY , LiuJet al. Tumor-associated macrophages promote oxaliplatin resistance via METTL3-mediated m(6)A of TRAF5 and necroptosis in colorectal cancer. Mol. Pharm.18, 1026–1037 (2021).
   PubMedGoogle Scholar
• Jiang Z , HouZ , LiuW , YuZ , LiangZ , ChenS. Circular RNA protein tyrosine kinase 2 (circPTK2) promotes colorectal cancer proliferation, migration, invasion and chemoresistance. Bioengineered13, 810–823 (2022).
   PubMed Web of Science ®Google Scholar
• Nishizawa Y , KonnoM , AsaiAet al. Oncogene c-Myc promotes epitranscriptome m(6)A reader YTHDF1 expression in colorectal cancer. Oncotarget9, 7476–7486 (2018).
   PubMedGoogle Scholar
• Taketo K , KonnoM , AsaiAet al. The epitranscriptome m6A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cells. Int. J. Oncol.52, 621–629 (2018).
   PubMed Web of Science ®Google Scholar
• Zhao S , LiuJ , NangaPet al. Detailed modeling of positive selection improves detection of cancer driver genes. Nat. Commun.10, 3399 (2019).
   PubMed Web of Science ®Google Scholar
• Li X , TangJ , HuangWet al. The m6A methyltransferase METTL3: acting as a tumor suppressor in renal cell carcinoma. Oncotarget8, 96103–96116 (2017).
   PubMedGoogle Scholar
• Barbieri I , TzelepisK , PandolfiniLet al. Promoter-bound METTL3 maintains myeloid leukaemia by m6A-dependent translation control. Nature552, 126–131 (2017).
   PubMed Web of Science ®Google Scholar
• Vu LP , PickeringBF , ChengYet al. The N6-methyladenosine (m6A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells. Nat. Med.23, 1369–1376 (2017).
   PubMed Web of Science ®Google Scholar
• Weng H , HuangH , WuHet al. METTL14 inhibits hematopoietic stem/progenitor differentiation and promotes leukemogenesis via mRNA m6A modification. Cell Stem Cell22, 191–205.e934 (2018).
   PubMed Web of Science ®Google Scholar
• Cui Q , ShiH , YePet al. m6A RNA methylation regulates the self-renewal and tumorigenesis of glioblastoma stem cells. Cell Rep.18, 2622–2634 (2017).
   PubMed Web of Science ®Google Scholar
• Ma JZ , YangF , ZhouCCet al. METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N6-methyladenosine-dependent primary microRNA processing. Hepatology65, 529–543 (2017).
   PubMed Web of Science ®Google Scholar
• Chen M , WeiL , LawCTet al. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2. Hepatology67, 2254–2270 (2018).
   PubMed Web of Science ®Google Scholar
• Cully M . Chemical inhibitors make their RNA epigenetic mark. Nat. Rev. Drug Discov.18, 892–894 (2019).
   PubMed Web of Science ®Google Scholar
• Guo J , TangH-W , LiJ , PerrimonN , YanD. Xio is a component of the Drosophila sex determination pathway and RNA N6-methyladenosine methyltransferase complex. Proc. Natl Acad. Sci.115, 3674–3679 (2018).
   PubMed Web of Science ®Google Scholar
• Su S , LiS , DengTet al. Cryo-EM structures of human m6A writer complexes. Cell Res.32(11), 982–994 (2022).
   PubMed Web of Science ®Google Scholar
• Bawankar P , LenceT , PaolantoniCet al. HAKAI is required for stabilization of core components of the m6A mRNA methylation machinery. Nat. Commun.12(1), 3778 (2021).
   PubMed Web of Science ®Google Scholar
• Chen Z , HuY , JinLet al. The emerging role of N6-methyladenosine RNA methylation as regulators in cancer therapy and drug resistance. Front. Pharmacol.13, 873030 (2022).
   PubMed Web of Science ®Google Scholar
• He L , LiH , WuA , PengY , ShuG , YinG. Functions of N6-methyladenosine and its role in cancer. Mol. Cancer18, 176 (2019).
   PubMed Web of Science ®Google Scholar
• Shi H , WeiJ , HeC. Where, when, and how: context-dependent functions of RNA methylation writers, readers, and erasers. Mol. Cell74, 640–650 (2019).
   PubMed Web of Science ®Google Scholar
• Sun T , WuR , MingL. The role of m6A RNA methylation in cancer. Biomed. Pharmacother.112, 108613 (2019).
   PubMed Web of Science ®Google Scholar
• Wang X , FengJ , XueYet al. Structural basis of N(6)-adenosine methylation by the METTL3–METTL14 complex. Nature534, 575–578 (2016).
   PubMed Web of Science ®Google Scholar
• Dai D , WangH , ZhuL , JinH , WangX. N6-methyladenosine links RNA metabolism to cancer progression. Cell Death Dis.9, 124 (2018).
   PubMed Web of Science ®Google Scholar
• Zhu W , WangJZ , WeiJF , LuC. Role of m6A methyltransferase component VIRMA in multiple human cancers (review). Cancer Cell Int.21, 172 (2021).
   PubMed Web of Science ®Google Scholar
• Yue Y , LiuJ , CuiXet al. VIRMA mediates preferential m(6)A mRNA methylation in 3′UTR and near stop codon and associates with alternative polyadenylation. Cell Discov.4, 10 (2018).
   PubMed Web of Science ®Google Scholar
• Zhu D , ZhouJ , ZhaoJet al. ZC3H13 suppresses colorectal cancer proliferation and invasion via inactivating Ras-ERK signaling. J. Cell. Physiol.234, 8899–8907 (2019).
   PubMed Web of Science ®Google Scholar
• Wang T , KongS , TaoM , JuS. The potential role of RNA N6-methyladenosine in cancer progression. Mol. Cancer19, 88 (2020).
   PubMed Web of Science ®Google Scholar
• Knuckles P , LenceT , HaussmannIUet al. Zc3h13/Flacc is required for adenosine methylation by bridging the mRNA-binding factor Rbm15/Spenito to the m(6)A machinery component Wtap/Fl(2)d. Genes Dev.32, 415–429 (2018).
   PubMed Web of Science ®Google Scholar
• Wen J , LvR , MaHet al. Zc3h13 regulates nuclear RNA m(6)A methylation and mouse embryonic stem cell self-renewal. Mol. Cell69, 1028–1038.e6 (2018).
   PubMed Web of Science ®Google Scholar
• Liu ZX , LiLM , SunHL , LiuSM. Link between m6A modification and cancers. Front. Bioeng. Biotechnol.6, 89 (2018).
   PubMed Web of Science ®Google Scholar
• Sazonova EV , KopeinaGS , ImyanitovEN , ZhivotovskyB. Platinum drugs and taxanes: can we overcome resistance?Cell Death Discov.7, 155 (2021).
   PubMed Web of Science ®Google Scholar
• Ghosh S . Cisplatin: the first metal based anticancer drug. Bioorg. Chem.88, 102925 (2019).
   PubMed Web of Science ®Google Scholar
• Rosenberg B , VancampL , KrigasT. Inhibition of cell division in Escherichia Coli by electrolysis products from a platinum electrode. Nature205, 698–699 (1965).
   PubMed Web of Science ®Google Scholar
• Yu X , ZhengH , ChanMT , WuWK. Modulation of chemoresponsiveness to platinum-based agents by microRNAs in cancer. Am. J. Cancer Res.7, 1769–1778 (2017).
   PubMed Web of Science ®Google Scholar
• Manohar S , LeungN. Cisplatin nephrotoxicity: a review of the literature. J. Nephrol.31, 15–25 (2018).
   PubMed Web of Science ®Google Scholar
• Fang CY , LouDY , ZhouLQet al. Natural products: potential treatments for cisplatin-induced nephrotoxicity. Acta Pharmacol. Sin.42, 1951–1969 (2021).
   PubMed Web of Science ®Google Scholar
• Riddell IA . Cisplatin and oxaliplatin: our current understanding of their actions. Met. Ions Life Sci.18, 1–42 (2018).
   Google Scholar
• Tan S , PengX , PengW , ZhaoY , WeiY. Enhancement of oxaliplatin-induced cell apoptosis and tumor suppression by 3-methyladenine in colon cancer. Oncol. Lett.9, 2056–2062 (2015).
   PubMed Web of Science ®Google Scholar
• Cassidy J . Review of oxaliplatin: an active platinum agent in colorectal cancer. Int. J. Clin. Pract.54, 399–402 (2000).
   PubMed Web of Science ®Google Scholar
• Wei J , YinY , ZhouJet al. METTL3 potentiates resistance to cisplatin through m(6)A modification of TFAP2C in seminoma. J. Cell Mol. Med.24, 11366–11380 (2020).
   PubMed Web of Science ®Google Scholar
• Chen H , XiangY , YinYet al. The m6A methyltransferase METTL3 regulates autophagy and sensitivity to cisplatin by targeting ATG5 in seminoma. Transl. Androl. Urol.10, 1711–1722 (2021).
   PubMed Web of Science ®Google Scholar
• Zhang R , LiSW , LiuL , YangJ , HuangG , SangY. TRIM11 facilitates chemoresistance in nasopharyngeal carcinoma by activating the β-catenin/ABCC9 axis via p62-selective autophagic degradation of DAPLE. Oncogenesis9, 45 (2020).
   PubMed Web of Science ®Google Scholar
• Jin D , GuoJ , WuYet al. m(6)A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis. J. Hematol. Oncol.14, 32 (2021).
   PubMed Web of Science ®Google Scholar
• Uddin MB , RoyKR , HosainSBet al. An N(6)-methyladenosine at the transited codon 273 of p53 pre-mRNA promotes the expression of R273H mutant protein and drug resistance of cancer cells. Biochem. Pharmacol.160, 134–145 (2019).
   PubMed Web of Science ®Google Scholar
• Li H , WangC , LanLet al. METTL3 promotes oxaliplatin resistance of gastric cancer CD133+ stem cells by promoting PARP1 mRNA stability. Cell. Mol. Life Sci.79, 135 (2022).
   PubMed Web of Science ®Google Scholar
• Ma H , ShenL , YangH , GongH , DuX , LiJ. m6A methyltransferase Wilms’ tumor 1-associated protein facilitates cell proliferation and cisplatin resistance in NK/T cell lymphoma by regulating dual-specificity phosphatases 6 expression via m6A RNA methylation. IUBMB Life73, 108–117 (2021).
   PubMed Web of Science ®Google Scholar
• Wei W , SunJ , ZhangHet al. Circ0008399 Interaction with WTAP promotes assembly and activity of the m(6)A methyltransferase complex and promotes cisplatin resistance in bladder cancer. Cancer Res.81, 6142–6156 (2021).
   PubMed Web of Science ®Google Scholar
• Wang Q , XieH , PengH , YanJ , HanL , YeG. ZC3H13 inhibits the progression of hepatocellular carcinoma through m(6)A-PKM2-mediated glycolysis and enhances chemosensitivity. J. Oncol.2021, 1328444 (2021).
   PubMed Web of Science ®Google Scholar
• Miranda-Gonçalves V , LoboJ , Guimarães-TeixeiraCet al. The component of the m(6)A writer complex VIRMA is implicated in aggressive tumor phenotype, DNA damage response and cisplatin resistance in germ cell tumors. J. Exp. Clin. Cancer Res.40, 268 (2021).
   PubMed Web of Science ®Google Scholar
• Zhang Y , GaoLX , WangW , ZhangT , DongFY , DingWP. m(6) A demethylase fat mass and obesity-associated protein regulates cisplatin resistance of gastric cancer by modulating autophagy activation through ULK1. Cancer Sci.113(9), 3085–3096 (2022).
   PubMed Web of Science ®Google Scholar
• Shriwas O , PriyadarshiniM , SamalSKet al. DDX3 modulates cisplatin resistance in OSCC through ALKBH5-mediated m(6)A-demethylation of FOXM1 and NANOG. Apoptosis25, 233–246 (2020).
   PubMed Web of Science ®Google Scholar
• Yu H , YangX , TangJet al. ALKBH5 inhibited cell proliferation and sensitized bladder cancer cells to cisplatin by m6A-CK2α-mediated glycolysis. Mol. Ther. Nucleic Acids23, 27–41 (2021).
   PubMedGoogle Scholar
• Chen P , LiuXQ , LinX , GaoLY , ZhangS , HuangX. Targeting YTHDF1 effectively re-sensitizes cisplatin-resistant colon cancer cells by modulating GLS-mediated glutamine metabolism. Mol. Ther. Oncolytics20, 228–239 (2021).
   PubMed Web of Science ®Google Scholar
• Sun Y , DongD , XiaY , HaoL , WangW , ZhaoC. YTHDF1 promotes breast cancer cell growth, DNA damage repair and chemoresistance. Cell Death Dis.13, 230 (2022).
   PubMed Web of Science ®Google Scholar
• Shi Y , FanS , WuMet al. YTHDF1 links hypoxia adaptation and non-small cell lung cancer progression. Nat. Commun.10, 4892 (2019).
   PubMed Web of Science ®Google Scholar
• Huang CS , ZhuYQ , XuQCet al. YTHDF2 promotes intrahepatic cholangiocarcinoma progression and desensitises cisplatin treatment by increasing CDKN1B mRNA degradation. Clin. Transl. Med.12, e848 (2022).
   PubMed Web of Science ®Google Scholar
• Zhao Y , ZhaoH , ZhangDet al. YTHDF3 facilitates eIF2AK2 and eIF3A recruitment on mRNAs to regulate translational processes in oxaliplatin-resistant colorectal cancer. ACS Chem. Biol.17, 1778–1788 (2022).
   PubMedGoogle Scholar
• Zhang Z , ZhangC , YangZet al. m6A regulators as predictive biomarkers for chemotherapy benefit and potential therapeutic targets for overcoming chemotherapy resistance in small-cell lung cancer. J. Hematol. Oncol.14(1), 190 (2021).
   PubMed Web of Science ®Google Scholar